Table 1.
Baseline demographics, clinical characteristics, mean striatal DaT SBR and BMP concentrations (adjusted for age and sex) in LRRK2, sPD and HC cohorts.
| a Comparison of LRRK2 G2019S sub-cohorts to sPD and HC | ||||||||
|---|---|---|---|---|---|---|---|---|
| Cohort | 1 | 2 | 3 | 4 | ||||
| G2019S + PD n = 134 | G2019S + NMC n = 182 | sPD n = 379 | HC n = 190 | P Value 1 vs 2 | P Value 1 vs 3 | P Value 2 vs 4 | P Value 3 vs 4 | |
| Age (years), mean (SD)a | 63.26 (9.20) | 62.33 (7.72) | 61.94 (9.66) | 60.67 (11.16) | ||||
| Age at onset (years), mean (SD) | 58.05 (9.99) | 59.94 (9.93) | N/A | 0.0609 | N/A | N/A | ||
|
Mean Striatal DaT SBR, mean (SD) missing |
1.29 (0.38) | 2.52 (0.52) | 1.39 (0.39) | 2.57 (0.56) | <0.0001 | 0.0093 | 0.4164 | <0.0001 |
| 15 | 9 | 4 | 3 | |||||
|
Disease duration (months), median (range) |
28.55 | 4.2 | N/A | <0.0001α | N/A | N/A | ||
| (0.97, 104.43) | (0.40, 35.83) | |||||||
| Female Sex, n (%) | 65 (48.51%) | 104 (57.14%) | 129 (34.04%) | 67 (35.26%) | 0.1283 | 0.0030 | <0.0001 | 0.7716 |
|
MDS-UPDRS III Off, mean (SD) missing |
22.46 (11.45) | 3.14 (4.11) | 20.89 (8.79) | 1.19 (2.15) | <0.0001 | 0.2097 | <0.0001 | <0.0001 |
| 36 | 0 | 0 | 2 | |||||
|
MoCA, median (range) missing |
27 | 27 | 28 | 28 | 0.2689α | 0.0010α | <0.0001α | <0.0001α |
| (13.00, 30.00) | (18.00, 30.00) | (17.00, 30.00) | (26.00, 30.00) | |||||
| 2 | 1 | 0 | 0 | |||||
| Total di-18:1-BMP, median (range) | 12.60 | 13.88 | 3.53 | 3.77 | 0.2246 | <0.0001 | <0.0001 | 0.8823 |
| (1.29, 160.95) | (0.90, 71.97) | (0.21, 38.02) | (0.39, 22.03) | |||||
| Total di-22:6-BMP, median (range) | 65.63 | 63.79 | 10.61 | 10.42 | 0.8082 | <0.0001 | <0.0001 | 0.5976 |
| (9.85, 307.69) | (8.65, 245.60) | (1.18, 76.76) | (1.25, 85.89) | |||||
| 2,2’-di-22:6-BMP, median (range) | 51.39 | 49.38 | 6.83 | 6.37 | 0.9820 | <0.0001 | <0.0001 | 0.6946 |
| (6.22, 240.68) | (6.99, 248.17) | (0.81, 59.27) | (0.60, 65.96) | |||||
| b Comparison of LRRK2 R1441G sub-cohorts to sPD, and HC | |||||||
|---|---|---|---|---|---|---|---|
| Cohort | 1 | 2 | 3 | 4 | |||
| R1441G + PD n = 15 | R1441G + NMC n = 15 | sPD n = 379 | HC n = 190 | P Value 1 vs 2 | P Value 1 vs 3 | P Value 2 vs 4 | |
| Age (years), mean (SD) | 64.51 (10.46) | 56.82 (5.09) | 61.94 (9.66) | 60.67 (11.16) | 0.0186 | 0.3650 | 0.0192 |
| Age at onset (years), mean (SD) | 60.70 (11.74) | 59.94 (9.93) | N/A | 0.8069 | N/A | ||
|
Mean Striatal DaT SBR, mean (SD) missing |
1.37 (0.33) | 2.64 (0.68) | 1.39 (0.39) | 2.57 (0.56) | <0.0001 | 0.7551 | 0.7039 |
| 0 | 0 | 4 | 3 | ||||
|
Disease duration (months), median (range) |
24.8 | 4.2 | N/A | <0.0001α | N/A | ||
| (4.10, 77.80) | (0.40, 35.83) | ||||||
| Female Sex, n (%) | 11 (73.33%) | 10 (66.67%) | 129 (34.04%) | 67 (35.26%) | 0.6903 | 0.0018 | 0.0156 |
|
MDS-UPDRS III Off, mean (SD) missing |
15.86 (5.57) | 2.29 (3.31) | 20.89 (8.79) | 1.19 (2.15) | <0.0001 | 0.0053 | 0.2421 |
| 1 | 1 | 0 | 2 | ||||
|
MoCA, median (range) missing |
25 | 28 | 28 | 28 | 0.0494α | 0.0011α | 0.0812α |
| (18.00, 30.00) | (22.00, 30.00) | (17.00, 30.00) | (26.00, 30.00) | ||||
| 0 | 0 | 0 | 0 | ||||
| Total di-18:1-BMP, median (range) | 14.25 | 22.65 | 3.53 | 3.77 | 0.3133 | <0.0001 | <0.0001 |
| (5.04, 39.26) | (5.40, 72.51) | (0.21, 38.02) | (0.39, 22.03) | ||||
| Total di-22:6-BMP, median (range) | 71.52 | 47.27 | 10.61 | 10.42 | 0.3584 | <0.0001 | <0.0001 |
| (30.90, 136.67) | (19.15, 121.85) | (1.18, 76.76) | (1.25, 85.89) | ||||
| 2,2’-di-22:6-BMP, median (range) | 49.43 | 36.29 | 6.83 | 6.37 | 0.2203 | <0.0001 | <0.0001 |
| (17.82, 116.30) | (11.50, 101.43) | (0.81, 59.27) | (0.60, 65.96) | ||||
Pairwise comparisons that showed significance at p value <0.0125 (after Bonferroni correction applied due to multiple comparison) are shown in bolded font.
PD Parkinson’s disease, NMC non-manifesting carriers, sPD sporadic PD, HC healthy control, SD standard deviation, DaT dopamine transporter, SBR specific binding ratio, MDS-UPDRS movement disorders society-unified Parkinson’s disease rating scale, MoCA Montreal cognitive assessment, BMP bis(monoacylglycerol)phosphate.
αComputed using Mann–Whitney U-test.
aThe overall F-test was non-significant thus pairwise comparisons were not computed.